Ilcn Multidisciplinary Forum: Understanding Treatment Options And Resistance In Egfr-Positive Nsclc

ILCN Multidisciplinary Forum: Understanding Treatment Options and Resistance in EGFR-positive NSCLC

ILCN Multidisciplinary Forum: The Role of Liquid Biopsy in NSCLC

2020 TTF EGFR Breakout PIOTROWSKA Part 1 - Current Options Upon Acquired Resistance to Osimertinib

GRACE - Global Resource for Advancing Cancer Education

EGFR-Mutant Lung Cancer & Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum

Dana-Farber Cancer Institute

Future Research and Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum

Dana-Farber Cancer Institute

NSCLC: EGFR Inhibition and Resistance Mechanisms

Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC

GRACE - Global Resource for Advancing Cancer Education

Resistance Mechanisms in EGFR-Positive NSCLC

Acquired Resistance to Osimertinib in EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum - English

GRACE - Global Resource for Advancing Cancer Education

Understanding NSCLC Treatment When You Have an EGFR Mutation

You and Lung Cancer

How, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR positive NSCLC

Investigating EGFR resistance mutations in routine genomic profiling

Current treatment recommendations and future directions for EGFR-mutant NSCLC

Treatment Options: Newly Diagnosed EGFR+ NSCLC

Targeted Oncology

EGFR Initial Treatment, Acquired Resistance and Q&A with H. Jack West, MD and Helena Yu, MD

GRACE - Global Resource for Advancing Cancer Education

Treatment Options for EGFR T790M Negative Acquired Resistance

GRACE - Global Resource for Advancing Cancer Education

2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2

Total Health | Oncology

Resistance Mechanisms in EGFR+ NSCLC Treatment - Targeted Therapies in Lung Cancer 2023

GRACE - Global Resource for Advancing Cancer Education

15 Years of Advances in EGFR Mutant Lung Cancer

Yale Cancer Center

Understanding, preventing, and delaying EGFR resistance in the era of Osimertinib